
Commentary|Videos|January 30, 2025
Adding Blinatumomab to Consolidation Therapy in Older Patients With Newly Diagnosed, BCR::ABL1–Negative B-ALL
Author(s)George Yaghmour, MD, Rachel Elizabeth Rau, MD
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on blinatumomab as consolidation therapy in older patients with newly diagnosed ALL.
Advertisement
Episodes in this series

Advertisement
Related to this article

Maintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.

The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
3
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5

